Our proprietary nanotherapeutics are designed to enable the distribution of water insoluble drugs in the blood circulation, improve pharmacokinetics, and facilitate drug accumulation in the failing heart.
Cardiol’s nanotherapeutics are based on a patented family of biocompatible and biodegradable amphiphilic block co-polymers made from polyethylene glycol (PEG) and polycaprolactone (PCL). Both PEG and PCL have a long history of safe use in humans. A functionalized polyester based on PCL (PBCL) forms the lipophilic core of the nanoparticles, allowing both the solubilization and encapsulation of lipid-soluble drugs (see diagram below). PEG forms the water-compatible surface layer of the nanoparticles, enabling the encapsulated drug to circulate in the aqueous environment of the blood. Cardiol’s proprietary nanoparticles not only have improved inherent stability and biocompatibility, they can also be customized to optimize the encapsulation and release characteristics of a broad range of pharmaceuticals.
Patented Nanotechnology For Drug Formulation